Prelude Therapeutics Incorporated
PRLD
$1.21
-$0.03-2.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -31.23M | -32.09M | -28.73M | -32.27M | -34.74M |
| Total Depreciation and Amortization | 433.00K | 435.00K | 489.00K | 405.00K | 452.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.98M | 4.30M | 3.21M | 5.50M | 5.16M |
| Change in Net Operating Assets | 739.00K | -6.88M | 4.29M | -933.00K | 6.07M |
| Cash from Operations | -26.08M | -34.23M | -20.74M | -27.30M | -23.06M |
| Capital Expenditure | -20.00K | -47.00K | -53.00K | -63.00K | -359.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.54M | 62.23M | 22.17M | 10.80M | 26.48M |
| Cash from Investing | 11.52M | 62.19M | 22.12M | 10.73M | 26.12M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -53.00K | -155.00K | -151.00K | -148.00K | -96.00K |
| Issuance of Common Stock | 92.00K | -- | 124.00K | 56.00K | 257.00K |
| Repurchase of Common Stock | -2.00K | -5.00K | -7.00K | -13.00K | -18.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | -26.00K | -84.00K |
| Cash from Financing | 37.00K | -160.00K | -34.00K | -131.00K | 59.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.52M | 27.80M | 1.34M | -16.69M | 3.12M |